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Abstract
Staphylococcus aureus is the most frequent causative organism of osteomyelitis. It is characterised by widespread bone loss
and bone destruction. Previously we demonstrated that S. aureus protein A (SpA) is capable of binding to tumour necrosis
factor receptor-1 expressed on pre-osteoblastic cells, which results in signal generation that leads to cell apoptosis resulting
in bone loss. In the current report we demonstrate that upon S. aureus binding to osteoblasts it also inhibits de novo bone
formation by preventing expression of key markers of osteoblast growth and division such as alkaline phosphatase, collagen
type I, osteocalcin, osteopontin and osteocalcin. In addition, S. aureus induces secretion of soluble RANKL from osteoblasts
which in turn recruits and activates the bone resorbing cells, osteoclasts. A strain of S. aureus defective in SpA failed to affect
osteoblast growth or proliferation and most importantly failed to recruit or activate osteoclasts. These results suggest that S.
aureus SpA binding to osteoblasts provides multiple coordinated signals that accounts for bone loss and bone destruction
seen in osteomyelitis cases. A better understanding of the mechanisms through which S. aureus leads to bone infection may
improve treatment or lead to the development of better therapeutic agents to treat this notoriously difficult disease.
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Introduction
Bone tissue is composed of both mineral and organic material
designed specifically for strength and rigidity to support the load-
bearing structure of the body. Bone is constantly undergoing
remodelling from birth to death. This is a complex process
involving bone formation followed by bone resorption. The bone
remodelling process is tightly controlled by the coupled action of
osteoblasts and osteoclasts that sequentially carry out formation of
new bone followed by resorption of old bone [1].
Bone formation results from a complex cascade of events that
involve proliferation of primitive mesenchymal stem cells, differ-
entiation into matrix forming osteoblasts and finally mineralisa-
tion. During the osteoblast maturation phase, several markers of
osteoblast growth and division (osteoblastogenesis) are expressed
including alkaline phosphatase and type I collagen, both of which
are important for bone matrix deposition and mineralisation [2,3].
When fully differentiated, mature osteoblasts also produce
regulators of matrix mineralisation such as osteocalcin, osteopon-
tin and osteonectin [4]. Bone resorption is mediated by activated
multinucleated osteoclasts [5] that are derived from mononuclear
precursor cells of the monocyte-macrophage lineage in the bone
marrow [6]. Receptor activator of nuclear factor (NF)-kB ligand
(RANKL) is the dominating cytokine regulating osteoclast
differentiation and proliferation (osteoclastogenesis). It is produced
predominantly by osteoblasts in membrane-bound and soluble
forms [7].
Bone is a sterile organ system that is highly resistant to bacterial
infection. However, a small number of organisms have a
predilection for the skeleton. Such breaches can lead to serious
bone disease such as septic arthritis [8] and osteomyelitis [9] which
often cause serious morbidity [10]. Bacteria can reach the bone by
haematogenous spread, direct inoculation or from a contiguous
focus of infection. The bloodstream may be invaded from a breach
in the skin, infected wound or infected umbilical cord. Direct
inoculation of bone can occur from penetrating injuries, open
fractures, joint replacements and surgical contamination. Contig-
uous sources may occur when infection is transmitted from local
tissue in the cases where infection in diabetics spread from soft
tissues to bone [11]. Inflammation, which often accompanies
infection, compresses the vasculature thus preventing immune cells
from reaching the infected area. Bone devoid of blood supply
detaches from the healthy bone to form a sequestrum which is
inaccessible to immune cells [12]. Treatment is often unsuccessful
as the infected nidus that harbours sessile matrix-protected
pathogens is impermeable to antibiotics and often requires radial
debridement coupled with systemic antibiotic treatment [13].
Although a broad range of bacterial species have been isolated
in cases of septic arthritis, osteoitis and osteomeylitis, Staphylococcus
aureus is the main offender, accounting for between 37% to 80% of
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cases [11]. S. aureus is a normal commensal of the human body and
usually lives in harmony with its host without causing symptoms.
Its primary habitat is the anterior nares in 20% of the population
and is transiently associated with the rest [14]. The success of S.
aureus as an opportunistic pathogen is due in part to its expression
of a wide array of microbial surface components recognising
adhesive matrix molecules (MSCRAMM’s) [15]. Using these
MSCRAMM’s S. aureus can attach either directly or indirectly to
host cells including bone cells [16,17,18,19].
Protein A is an MSCRAMM and is an important virulence
factor of S. aureus [14]. It binds a number of plasma proteins,
including the Fc portion of IgG [20], the Fab-heavy chain of the
Vh3 region of IgM molecules [21] and vonWillebrand factor [22],
as well as tumour necrosis factor receptor-1 (TNFR-1) [23,24] and
the epidermal growth factor receptor (EGFR) [25]. SpA comprises
an N-terminal ligand binding domain (E, D, A, B, C) linked to the
cell wall peptidoglycan via the C-terminal LPXTG motif [26].
When bone tissue gets infected it upsets the normal process of
bone remodelling that is orchestrated by osteoclasts and osteo-
blasts. While many attempts have been made to understand the
mechanisms involved, most studies have focused on the effect S.
aureus has on osteoblasts. Early studies demonstrated S. aureus
fibronectin binding proteins (FnbpA and FnbpB) can bind to
osteoblasts. This interaction leads to internalisation of S. aureus into
phagocytic vesicles in the osteoblast [18]. This process renders the
bacteria safe from either immune or antibiotic attack. More
recently, our group demonstrated that S. aureus SpA can bind
directly to pre-osteoblastic cells via Tumour Necrosis Factor
Receptor-1 (TNFR-1) without the presence of an extra cellular
matrix [19]. Engagement of this receptor results in signal
generation that leads to osteoblast apoptosis preventing new bone
formation [19]. While these studies provide critical information in
the way osteoblast cells respond to S. aureus in bone formation, they
did not explain effects on bone loss or resorption. In this paper we
demonstrate that when S. aureus binds to osteoblast cells, in
addition to inducing apoptosis, it stunts osteoblast cell growth
(osteoblastogenesis). Furthermore, S. aureus also induces expression
of soluble RANKL by osteoblasts which in turn recruits osteoclasts
and promotes their formation and proliferation. This increases the
bone resorptive power of osteoclasts which further weakens the
skeleton. Deletion of SpA from S. aureus abolishes all of these
responses suggesting that SpA is a double-edged sword, which
inhibits osteoblast growth while at the same time increasing bone
resorption. A better understanding of the mechanisms leading to
bone infection may aid in the improved treatment or development
of novel therapies to treat this disease.
Results
S. aureus Inhibits Osteoblast Proliferation Over a 21 Day
Period
Previously we demonstrated that S. aureus SpA promotes
adherence to pre-osteoblastic cells in non-osteogenic culture
[19]. In order to further understand the nature of this interaction
we investigated the ability of committed osteoblasts to proliferate
in the presence of pro-osteogenic media conditions and S. aureus
over a 21 day period. This was in order to demonstrate that S.
aureus still inhibits proliferation in the presence of an extra cellular
matrix produced by osteoblasts and that SpA/TNFR1 interaction
occurs despite the presence of a matrix. S. aureus were formalde-
hyde fixed to prevent loss of essential nutrients necessary for
osteoblast growth and proliferation. Consistent with previous
results formaldehyde fixation did not have any effect on SpA as
determined by Western immunoblotting [19]. SpA surface
expression was confirmed on S. aureus strains Newman wildtype
and the complemented strain, while Newman DSpA was deficient
in this protein (data not shown).
Formaldehyde-fixed S. aureus were added to osteoblasts and cell
counts were obtained at day 7, 14 and 21 using a haemocytometer
(Figure 1A). Images were obtained using brightfield microscopy
(Figure 1B). Uninfected osteoblasts proliferated normally over the
21 day period. Addition of S. aureus prevented osteoblasts from
proliferation over the course of the 21 days compared to the
uninfected osteoblasts (P,0.0001, n= 5). Addition of a mutant
defective in expression of SpA allowed proliferation of osteoblasts
significantly more than the S. aureus infected osteoblasts
(P,0.0001, n= 5) but not as much as the uninfected osteoblasts
(P,0.0001, n= 5). Complementation of S. aureus mutant with
pCU1spa restored the inhibition of proliferation below levels
observed in the wildtype (P,0.001, n= 5). These results collec-
tively demonstrate that when S. aureus SpA binds to differentiating
osteoblasts it prevents their growth and proliferation.
S. aureus Inhibits Osteogenesis Markers Over a 21 Day
Period
We next investigated the effect S. aureus has on new bone
formation (osteogenesis). Alkaline phosphatase is an enzyme found
in osteoblasts and is a biochemical indicator of early stage
osteogenesis. Osteoblasts were added to formaldehyde fixed S.
aureus and the alkaline phosphatase content was measured at day 7,
14 and 21. Uninfected osteoblasts had a consistent increase in
alkaline phosphatase over the 21 day period suggesting in vitro
bone formation/mineralisation (Figure 2A). Addition of wildtype
S. aureus Newman expressing SpA significantly inhibited alkaline
phosphatase levels at day 14 and day 21 compared to uninfected
osteoblasts (P,0.05, n= 3). In contrast to this, addition of a S.
aureus mutant defective in expression of SpA failed to affect alkaline
phosphatase at either day 7, 14 or 21 (P=NS, n= 3). The
complemented mutant regained the inhibition effect to the same
level as the wildtype S. aureus strain at day 7 and 14 compared to
the uninfected osteoblasts (P,0.05, n= 3). At day 21 there was a
significant drop in alkaline phosphatase content possibly due to
osteoblast cell death. This may be explained by the over-
expression of SpA on the surface of the complemented strain
and the previous findings that S. aureus SpA can induce cell
apoptosis.
During the process of osteogenesis, osteoblasts secrete proteins
that form a matrix for newly proliferated osteoblasts to adhere to.
Such matrix proteins include collagen type I, osteopontin and
osteocalcin. We investigated the effect that S. aureus has on these
osteogenic markers. To do this RNA was isolated from uninfected
and S. aureus-infected osteoblasts following 0, 7, 14 and 21 days.
Analysis of osteogenesis was carried out by quantitative real time
PCR and the gene expression was calculated as a fold change
compared with day 0 with either the uninfected or S. aureus
infected osteoblasts.
Collagen type I is an early stage marker of osteogenesis that is
typically expressed at day 7. Consistent with the literature there
was a 2-fold change in expression of collagen type I in the
uninfected osteoblasts at day 7 (Figure 2B). Expression gradually
decreased back to baseline at day 14 and 21 in the uninfected
osteoblasts. Addition of the wildtype S. aureus Newman strain, the
S. aureus DSpA or the complemented mutant, to osteoblasts
prevented the expression of collagen type I over 7, 14 or 21 days
(P,0.0001; all strains versus uninfected, n= 3).
Osteopontin is a mid stage markers of osteogenesis. There was
no significant increase in gene expression for osteopontin at day 0
for either the uninfected or S. aureus-infected osteoblasts (Fig 2C,
Staphylococcus aureus Induced Bone Destruction
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P=NS, n= 3). However at day 14 there was almost a 10-fold
increase in expression in uninfected compared to the S. aureus-
infected osteoblasts (P,0.05, n = 3) and an almost 15-fold increase
in expression in the uninfected osteoblasts at day 21 (P,0.01,
n = 3). Interestingly addition of the S. aureus DSpA mutant induced
higher expression of osteopontin at day 7 (P,0.01, n= 3) and a
similar level of expression at day 14 compared to the uninfected
osteoblasts (P =NS, n= 3). Expression of osteopontin was back to
baseline levels on day 21 following addition of the mutant defective
in SpA. Addition of the complemented strain failed to induce
expression of osteopontin (compared to uninfected cells
(P,0.0001, n= 3) with levels similar to the wildtype S. aureus
Newman.
Osteocalcin is a late stage marker of osteogenesis. Expression
was increased 18- and 25-fold respectively, at day 7 and 14
(Figure 2D, P,0.05, n = 3). At day 21 there was an almost 50-fold
increase in osteocalcin expression in the uninfected osteoblasts.
Addition of the wildtype S. aureus wildtype strain, the S. aureus
DSpA mutant or the complemented mutant to osteoblasts
prevented the expression of osteocalcin over 7, 14 or 21 days
(P,0.0001; all strains versus uninfected, n = 3).
S. aureus Induces RANKL Expression in Osteoblasts
A common characteristic of infected bone tissue is widespread
bone loss possibly due to increased bone resorption. RANKL is
produced by osteoblasts and is the main trigger for recruitment of
pre-osteoclasts and the subsequent trigger for bone resorption. We
next investigated if RANKL is released from osteoblasts following
infection with S. aureus. Quantitative analysis of soluble RANKL
on uninfected osteoblasts demonstrated a low level of RANKL
after 24 hrs. Addition of S. aureus Newman significantly increased
RANKL expression after 24 hrs in the soluble fraction (Fig 3;
P,0.01, n = 3). Addition of the S. aureus DSpA mutant failed to
express significant levels of soluble RANKL compared to the
uninfected sample (Fig 3; P=NS, n= 3). However, the comple-
mented mutant led to a significant expression of soluble RANKL
with levels significantly higher than the wildtype (Fig 3; P,0.001,
n = 3).
S. aureus Induces Migration of Pre-osteoclasts
We next investigated the migration of pre-osteoclasts toward S.
aureus-infected RANKL-expressing osteoblasts. By adapting a
previously described cell migration assay [27] it was possible to
calculate the migration of individual pre-osteoclasts towards
infected osteoblasts. Haemotoxylin stained pre-osteoclasts were
counted from 5 random fields of view and the average cell count
was established as indicative of the total cell migration. A small
number of pre-osteoclasts migrated towards the uninfected
osteoblasts following 18 hours of exposure (Figure 4A). Addition
of S. aureus to the osteoblasts induced a significant increase in the
number of pre-osteoclasts migrating in comparison to the
uninfected sample (P,0.05, n= 3). Addition of the S. aureus DSpA
Figure 1. Staphylococcus aureus prevents osteoblast growth and proliferation over a 21 day period. Osteoblasts (56105 cells/ml) were
preincubated with either control buffer (——) or formaldehyde fixed S. aureus Newman (-----), Newman Dspa (?????), or Newman spa (pCU1spa+) (— ?
—). (A) Following days 7, 14 and 21 osteoblasts were removed by trypsinization and proliferation was determined by counting cells on a
haemocytometer. (B) Osteoblasts were also visualised using an inverted bright field microscope (Leica, DMIL) at x200 magnification., *P,0.0001,
n = 5.
doi:10.1371/journal.pone.0040586.g001
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mutant failed to induce migration of the pre-osteoclasts above
uninfected levels (P =NS, n= 3). Finally addition of the S. aureus
complemented mutant led to a significant increase in the
migration of pre-osteoclasts (P,0.0001, n= 3).
S. aureus Induces Osteoclastogenesis
We next investigated whether S. aureus induced RANKL
binding to the RANK triggers osteoclastogenesis. To do this the
media was removed from osteoblasts infected with S. aureus, and
transferred to the pre-osteoclasts for 7, 14 or 21 days. This
conditioned media contains many secreted proteins from the
osteoblasts, most notably, RANKL. Tartrate-resistant acid phos-
phatase (TRAP) is a glycosylated monomeric metalloenzyme that
is highly expressed in osteoclasts and its detection is often used to
measure osteoclastogenesis. As expected, the numbers of osteo-
clasts formed in the media from uninfected osteoblasts (Figure 5)
rose steadily over the 21 day period. There was a significant
increase in osteoclast formation following addition of S. aureus
infected osteoblast media at day 7 (P,0.05, n = 5), 14 (P,0.0001,
n = 5) and 21 (P,0.0001, n = 5). The S. aureus DSpA mutant
reduced osteoclastogenesis to uninfected levels at day 7, 14 and 21
(P=NS, n= 5). Finally the numbers of osteoclasts growing in the
media from the S. aureus complemented mutant were significantly
increased and similar to the levels of the wildtype S. aureus
Newman strain at days 7 (P,0.005, n = 5), 14 (P,0.0001, n= 5)
and 21 (P,0.0001, n= 5).
Discussion
Bone remodelling involves the coupled action of bone-forming
osteoblasts and bone-resorbing osteoclasts. This process replaces
old bone with new bone to ensure the integrity of the load bearing
structure of the skeleton. This is a highly controlled sequence of
events by both local and systemic factors, and any upset in the
naturall balance between resorption and formation can lead to
accelerated bone loss, resulting in an increased risk of fractures due
Figure 2. Staphylococcus aureus prevents expression of osteogenic markers. Osteoblasts (56105 cells/well) were incubated with either
control buffer (——) or formaldehyde fixed S. aureus Newman (-----), Newman Dspa (?????), or Newman spa (pCU1spa+) (— ? —) for a period of 21
days. (A) Osteoblasts were lysed with 1 ml of lysis buffer containing a substrate for alkaline phosphatase (0.1 M Na acetate, 2% Triton X-100 and 10
mM p-nitrophenol phosphate) and incubated in the dark for 1 hour at 37uC. RNA was isolated and reverse transcribed to cDNA. Analysis of bone
formation marker expression was carried out specifically for the early bone marker (B) collagen type I, (C) osteopontin and (D) osteocalcin. *0.01,
**0.05, ***0.0001, n = 3.
doi:10.1371/journal.pone.0040586.g002
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to osteoporosis (which occurs due to an imbalance between
formation and resorption) or another pathological disease. One
potential mediator that can upset the process of bone remodelling
is the presence of an infectious micro-organism. Although typically
a sterile environment, trauma, bone surgery or placement of a
foreign device such as an orthopaedic implant may expose this
otherwise sterile environment to an infection. S. aureus is a
common commensal of the human skin and mucous membranes
and is the major pathogen isolated from patients with bone
infection. The pathology of infected bone tissue shows severe
inflammation, loss of vasculature and widespread bone destruction
and bone loss. Recently we demonstrated that S. aureus SpA binds
to the TNFR-1 which is expressed on osteoblasts [19]. This
interaction results in a premature signal that triggers apoptosis.
While this may account for some of the bone loss seen in infected
bone tissue, it does not account for the failure of pre-osteoblasts to
differentiate into fully mature matrix-producing osteoblasts or
indeed for the widespread bone destruction seen in infected tissue.
Therefore this study investigated additional factors that may
contribute specifically to bone loss and bone destruction.
Bone formation or osteogenesis is typically characterised by the
sequential expression of a series of bone formation markers
including type I collagen, alkaline phosphatase, osteopontin and
osteocalcin. Osteoblasts then eventually produce RANKL [28]
which acts as a signal for the recruitment, proliferation and
activation of osteoclasts which initiates the resorption phase.
During staphylococcal bone infection a number of cytokines are
released into the surrounding environment that critically affect
bone formation [29,30]. For example, TNFa is known to
Figure 3. Staphylococcus aureus induces expression of soluble
RANKL. Osteoblasts (16106 cells/well) were incubated with either
control buffer, S. aureus Newman, Newman Dspa or Newman spa
(pCU1spa+) for 24 hrs. Media from uninfected and infected osteoblasts
was removed and centrifuged at x 10,000g for 2 minutes. Soluble
RANKL was detected using an ELISA kit. *P,0.01, **P,0.001, n = 3
doi:10.1371/journal.pone.0040586.g003
Figure 4. Staphylococcus aureus induces the migration of pre-osteoclasts. Osteoblasts were cultured for 4 days, in the presence and absence
of S. aureus, before inserting hanging cell migration chamber inserts containing serum starved pre-osteoclasts. Following 18 hour incubation,
membranes from the migration chamber were removed and fixed in 4% formaldehyde. The membrane was then stained with haematoxylin (A) and
counted from 5 random fields of view (B). The average cell count was established as indicative of the total cell migration. *P,0.05, **P,0.001 n= 3.
doi:10.1371/journal.pone.0040586.g004
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independently control apoptosis and regulation of cell prolifera-
tion, both of which contribute to loss of bone formation [31]. As
TNFa is detectable only at low levels in osteoblasts [32] it is
unlikely that it is responsible for the inhibition of osteogenesis that
was observed in figure 2. Recently we demonstrated that S. aureus
SpA interacts with osteoblastic cells directly, by binding to the
TNF receptor [19]. This interaction triggers a proteolytic cascade,
by recruiting and activating the initiator caspases 3 and 6, resulting
in osteoblast apoptosis. The interaction between S. aureus SpA and
TNFR-1 may help explain the current results. In the current study
we found that S. aureus also inhibited osteogenesis by inhibiting
osteoblast proliferation and expression of alkaline phosphatase,
type I collagen, osteopontin and osteocalcin over a 21 day period
under pro-osteogenic in vitro culture conditions. A S. aureus mutant
deficient in SpA significantly recovered osteoblast alkaline
phosphatase and proliferation, suggesting that S. aureus binding
to the osteoblast TNF receptor controls these events similar to
TNFa binding to its receptor. For example, Gilbert et al.
demonstrated that TNFa binding to its receptor, TNFR1, inhibits
osteoblast differentiation independently of apoptosis in mice [33].
The importance of this observation is critical to the understanding
of the molecular mimicry that exists between bacterial cell wall
surface proteins and known host factors.
Interestingly the cells infected with the S. aureus mutant deficient
protein A failed to affect expression of type I collagen or
osteocalcin. One reason for this might be the role IL-1b plays in
bone formation. Several reports in the literature have demon-
strated that IL-1b inhibits expression of osteocalcin and type I
collagen [34,35]. IL-1b can be induced in human and murine
osteoblasts by a variety of stimuli including TNFa [36,37,38].
Indeed increased levels of IL-1b have been detected in several
animal models of bone infection [39]. Collectively these results
suggest that S. aureus SpA might be mimicking the effects of TNFa
by binding to TNFR-1. This interaction maybe responsible for
triggering apoptosis and inhibiting osteoblast proliferation and
differentiation simultaneously. At the same time osteoblasts release
the inflammatory cytokine IL-1b which inhibits expression of
osteogenic markers critical for matrix deposition and mineralisa-
tion, thus collectively contributing to bone loss. Additional
experiments are required to measure the release of IL1b following
infection with S. aureus in order to confirm this link.
Widespread bone destruction is also characteristic of an
infection in bone tissue and is typically mediated by activated
multinucleated osteoclasts. During the bone formation process
another cytokine, RANKL, is produced by osteoblasts which
serves to modulate the activity or formation of osteoclasts [7].
RANKL is a 317 amino acid polypeptide that is expressed either
on the surface of osteoblasts or released into the local environment,
and binds to and activates the RANK receptor expressed on
osteoclasts. Once activated, osteoclasts begin the resorption of
bone. However, the process of bone resorption needs to be tightly
controlled, as uncontrolled signals can lead to excessive bone
destruction and cause severe weakening of the skeletal system.
Consistent with previous results we found that S. aureus infection of
osteoblasts led to an increase in RANKL expression in their
membrane and also in a soluble form released into the
surrounding environment [40]. Previously it has been demon-
strated that expression of RANKL leads to the migration and
formation of osteoclasts, which is suggestive that S. aureus induced
bone infection initiates localised bone resorption. Here we
demonstrate that osteoclasts migrate toward S. aureus infected
osteoblasts releasing RANKL. More importantly, deletion of SpA
from S. aureus completely abolished RANKL expression and
ablated migration and proliferation of the osteoclasts. This is most
likely because S. aureus SpA is unable to bind to osteoblast TNFR-1
to induce release or expression of RANKL. These results are
consistent with the finding that TNFa binding to TNFR-1 on
osteoblasts results in increased RANKL expression which triggers
subsequent bone destruction [41,42]. RANKL is most likely
released with other pro-osteoclastogenic cytokines that induce
bone resorption e.g. Interleukin 6 [29]. Whether S. aureus SpA
regulates these other pro-osteoclastogenic or not requires further
investigation.
A picture of the mechanisms that leads to bone infection is
slowly starting to develop in the literature. Early reports
demonstrated that as a defence mechanism, S. aureus can become
internalised by osteoblasts. Uptake is promoted by fibronectin
binding proteins that capture fibronectin and use it as a bridge
between bacteria and the a5b1 integrin expressed on osteoblasts.
Integrin clustering results in signalling that lead to bacterial uptake
thus rendering the bacteria safe from both immune and antibiotic
attack [18]. In the current study we used a strain of S. aureus
(Newman) that does not express Fnbp’s on its surface [46]. In
addition, our group previously demonstrated that S. aureus strain
Newman can bind to osteoblasts even in the absence of fibronectin
or FnbpA and FnbpB [19]. These results suggest that a second
interaction between S. aureus and osteoblasts exists. Previously we
demonstrated that an early step in S. aureus infection of the bone
occurs when the major cell wall surface protein, SpA binds to
TNFR1 on osteoblasts. This triggers a series of events that lead to
induction of osteoblast apoptosis and inhibition of mineralisation
[19]. These events may account for the bone loss seen at infected
sites. In the current study we further develop these observations by
proposing a model though which S. aureus infection of bone can
also encourage bone resorption, thus accounting for bone
destruction. It is essential that bone is constantly turned over in
order to maintain strength and rigidity in the skeletal system. The
process of bone remodelling is tightly controlled by a series of
autocrine signals that control the correct amount of bone
resorption versus bone formation. Any significant deviation in
resorption and formation means accelerated bone loss and
increased risk of fractures and breaks. In the present study we
Figure 5. Staphylococcus aureus inhibits osteoclastogenesis. Pre-
osteoclasts were seeded (26104 cells/well) in 12-well tissue culture
plates and cultured for 21 days. Conditioned media from osteoblasts (4
days), with either control buffer (——) or formaldehyde fixed S. aureus
Newman (-----), Newman Dspa (?????), or Newman spa (pCU1spa+) (— ?
—) was then transferred to the pre-osteoclasts. Osteoclastogenesis was
determined by measuring tartarate resistant alkaline phosphatase
(TRAP). *P,0.05, **P,0.001 n= 5.
doi:10.1371/journal.pone.0040586.g005
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demonstrate that when S. aureus SpA binds to osteoblast TNFR-1 it
prevents expression of osteogenic markers essential for matrix
formation and bone formation (Table 1). Furthermore, binding of
S. aureus SpA to TNFR1 induces the release of soluble RANKL, a
cytokine critical for the migration of the bone resorbing cells, the
osteoclast (Table 2). Deletion of SpA prevents these events from
occurring. Put together these simultaneous signals will contribute
to the extensive bone loss and bone destruction observed in tissue
from bone infection patients. The final step in the infection process
occurs when the fibronectin binding proteins facilitate the
internalization of S. aureus into the osteoblast [18]. These
internalized S. aureus have also the ability to induce apoptosis via
the TRAIL/caspase pathway [43,44,45]. Given that a large
percentage of clinical isolates obtained from osteomyelitis cases
contain both protein A and the fibronectin binding proteins (both
greater than 80%) collectively the current and previous mecha-
nistic data suggest a multi-pronged approach is involved in bone
destruction and bone loss. One limitation of this study is that all
experiments have been carried out in vitro using cell culture
techniques, further experiments using animal models are required
to establish if these processes occur in vivo. A better understanding
of the mechanisms that lead to bone infection in vitro are required
before any in vivo experiments take place, such information may
lead to improved therapies to treat this disease.
Materials and Methods
Bacterial Strains and Growth Conditions
S. aureus strains used in this study are listed in Table 3. Bacteria
were grown overnight to the stationary growth phase at 37uC in
Brain Heart Infusion broth (Sigma-Aldrich, Ireland). S. aureus
strain Newman pCU1 (SpA+) was grown with the addition of
10 mg/ml chloramphenicol (Sigma-Aldrich, Ireland). S. aureus were
fixed in 4.8% formaldehyde (Sigma-Aldrich, Ireland) under
constant rotation for 10 minutes. Bacteria were then washed and
isolated by centrifugation at 4,000 g for 5 minutes and re-
suspended in phosphate buffered saline (PBS) (Sigma-Aldrich,
Ireland) at pH 7.4. S. aureus were adjusted to 16109 cells/ml for all
studies.
Tissue Cell Culture Conditions
The mouse clonal MC3T3-E1 pre-osteoblastic cell line (ATCC,
Middlesex, UK) was used for all experiments. This is a common
cell line used routinely for investigating osteoblast function. The
cells were cultured in standard T175 tissue culture flasks (Sarstedt,
Ireland) containing a-MEM supplemented with 10% FBS (Biosera
Ltd., United Kingdom), 2% penicillin-streptomycin solution and
1% L-glutamine (Sigma-Aldrich, Ireland). The media was
replaced every 3–4 days and after confluency, cells were harvested
using trypsin-EDTA (Sigma-Aldrich, Ireland) and re-suspended in
the standard medium. MC3T3-E1 pre-osteoblastic cells were
differentiated to matrix secreting mature osteoblasts using the
standard osteogenic cocktail, by supplementation of dexametha-
sone (100 nM), ascorbic acid (50 mg/ml) and b-glycercolpentahy-
drate (10 mM) (Sigma-Aldrich, Ireland).
The murine RAW 264.7 pre-osteoclast cell line (ATCC,
Middlesex, UK) was used for all osteoclast studies. This cell line
is commonly used to assess osteoclast function. Murine RAW
264.7 cells were cultured in T175 tissue culture flasks (Sarstedt,
Ireland) in high glucose Dulbecco’s Modified Eagles Medium
(DMEM) (Sigma-Aldrich, Ireland) supplemented with 10% heat
inactivated FBS (Biosera Ltd., United Kingdom) and 1%
penicillin-streptomycin solution (Sigma-Aldrich, Ireland).
Osteoblast Proliferation
S. aureus were allowed to adhere to 6 well plates for two hours at
37uC, in the presence of 5% CO2. To confirm uniformity of
adhesion between the various S. aureus strains (Newman wildtype,
Newman SpA-, Newman pCU1 SpA+) to the 6 well plates,
bacteria were stained with crystal violet (5%) for 10 mins and read
at 620 nm on a platelet reader. After 2 hours, unbound bacteria
were removed by gentle aspiration. MC3T3-E1 cells (56105 cells/
well) were then seeded onto the immobilised bacteria for 24 hrs.
Following 24 hrs the standard media was replaced with osteogenic
media. Osteoblasts were removed from the wells on days 7, 14,
and 21 days by trypsinization. Following this the cells were
pelleted by centrifugation and resuspended in 1 ml media.
Osteoblast proliferation was determined by counting cells on a
haemocytometer with a 1:1 dilution with Trypan Blue (Sigma-
Aldrich, Ireland), to distinguish between viable and non-viable
osteoblasts.
Assessment of Osteogenesis Markers
Alkaline phosphatase expression was evaluated by removing
osteoblast media and washing in warm PBS. Osteoblasts were
lysed with 1 ml of lysis buffer containing a substrate for acid
phosphatase (0.1 M Na acetate, 2% Triton X-100 and 10 mM p-
nitrophenol phosphate) and incubated in the dark for 1 hour at
37uC. The reaction was stopped using 0.3 M NaOH (Sigma-
Aldrich, Ireland). Triplicates (100 ml) of each well were then added
to a 96-well plate and absorbance was then read at A405nm, using a
microplate reader (Wallac Victor2, United Kingdom).
RNA was isolated from osteoblasts on days 0, 7, 14 and 21
respectively. Isolation was carried out by lysing the cells in RLT
lysis buffer (Qiagen, United Kingdom). The cell lysates were then
centrifuged in QI Shredder columns (Qiagen, United Kingdom)
and RNA was extracted using an RNeasy Mini Kit (Qiagen,
United Kingdom) according to the manufacturer’s instructions.
RNA concentration was quantified using a Nano-Drop (Mason
Technology, United Kingdom) spectrophotometer (absorption
260 nm). Subsequent to RNA extraction and quantification,
genomic DNA was removed and the RNA sample was reverse
transcribed using 300 ng of total RNA with an RT kit (QuantiTect
RT Kit, Qiagen, United Kingdom). Real-time polymerase chain
Table 1. Summary of the effects Staphylococcus aureus has on osteoblasts.
S. aureus strain Proliferation Alkaline Phosphatase Collagen type I Osteopontin Osteocalcin
No bacteria (control) + + + + +
Newman wildtype – – – – –
Newman SpA- + + – + –
Newman pCU1spa+ – – – – –
doi:10.1371/journal.pone.0040586.t001
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reaction (PCR) was then conducted using a 7500 Real-time PCR
System (Applied Biosystems, United Kingdom). The QuantiTect
SYBR Green PCR Kit (Qiagen, United Kingdom) was used
according to the manufacturer’s instructions, with QuantiTect
Primers (Qiagen, United Kingdom). Analysis of bone formation
marker expression was carried out specifically for the early bone
marker collagen type I, the mid/late stage markers, osteopontin
and osteocalcin (Qiagen, United Kingdom). Expression levels were
assessed using the relative quantification DDCt method and all
gene expression levels were normalised using the housekeeping
control 18S ribosomal RNA (Qiagen, United Kingdom).
Western Blot for Protein A
S. aureus Newman strains were lysed for 10 minutes on ice in
RIPA buffer supplemented with 1x protease inhibitor cocktail
(Sigma-Aldrich, Ireland). Protein lysate (10 mg) were separated on
a 10% sodium dodecylsulfate polyacrylamide (SDS-PAGE) gel.
Proteins were then transferred onto poly-vinyldifluoride mem-
branes (Roche, United Kingdom) for 1 hour. The membranes
were exposed to primary chicken anti-protein A IgY antibody
(clone SPA-27) overnight under constant rotation at 4uC.
Unbound antibody was removed from membranes by 10 minute
washes (x3) with Tris buffered saline (TBS) - 0.1% Tween buffer.
Protein bands were detected using species-specific horseradish
peroxidase-conjugated secondary antibody and developed by
chemiluminescence.
Quantification of Soluble RANKL
MC3T3-E1 osteoblastic cells (16106 cells/well) were cultured
for 7 days until confluency was reached and then cultured for a
further 24 hours, in the presence and absence of S. aureus, before
removing media which was placed on ice for analysis later. The
resulting uninfected and S. aureus infected osteoblast media was
centrifuged at 10,000 g for 2 minutes at 4uC to remove debris.
Soluble RANKL was detected using an ELISA kit (R&D Systems,
Minneapolis, MN) according to manufacturer’s instructions.
Migration of Pre-osteoclasts
RAW 264.7 pre-osteoclastic cells (26104 cells) were seeded in
8 mm pore hanging cell culture inserts (Millipore, Ireland) and
serum starved for 2 hours at 37uC, 5% CO2 in Optimem serum-
free media (Invitrogen, Ireland). S. aureus (16109 cells/ml) were
immobilised on 24-well plates and MC3T3-E1 osteoblastic cells
(56105 cells/well) were seeded as previously described. Osteoblasts
were cultured for 4 days, in the presence and absence of S. aureus,
to allow sufficient release of chemotaxis factors, before inserting
hanging cell migration chamber inserts containing serum starved
pre-osteoclasts. Pre-osteoclast cells were then incubated for 18
hours at 37uC, 5% CO2 to assess migration through the porous
membrane towards osteoblasts in presence and absence of S.
aureus. Following 18 hour incubation, membranes from the
migration chamber were removed and fixed in 4% formaldehyde.
The membrane was then stained with haematoxylin for 10
minutes before mounting on a glass slide. Pre-osteoclasts were
counted from 5 random fields of view and the average cell count
was established as indicative of the total cell migration. All images
were taken using an inverted bright field microscope (Leica,
DMIL) at x200 magnification.
Quantification of Tartate Resistant Acid Phosphate
(TRAP) as a Measure of Osteoclastogenesis
To determine the proliferation of pre-osteoclasts, RAW 264.7
cells were seeded (26104 cells/well) in 12-well tissue culture plates
in the presence of 100 ng/ml RANKL and cultured for 21 days.
Conditioned 4 day media from osteoblasts, either exposed or
unexposed to S. aureus, was then transferred to the pre-osteoclasts.
TRAP was quantified to measure osteoclastogenesis at day 7, 14
and 21 respectively. TRAP quantification was carried out by
removing conditioned media from pre-osteoclasts and washing
cells in PBS. Cells were then incubated for 1 hour at 37uC in
1 mM citrate solution. After the hour incubation, 20 ml was added
in triplicates to a 96-well plate containing 50 ml 100 mM p-
nitrophenol phosphate, 80 mM sodium tartrate, 200 mM sodium
citrate and 200 mM sodium chloride (Sigma-Aldrich, Ireland).
Table 2. Summary of the effects Staphylococcus aureus has on osteoclasts.
S. aureus strain RANKL OPG Migration of Osteoclasts Osteoclastogenesis
No bacteria (control) – + – –
Newman wildtype + – + +
Newman SpA– – + – –
Newman pCU1spa+ + – + +
doi:10.1371/journal.pone.0040586.t002
Table 3. List of strains of Staphylococcus aureus used in this study.
Strain or plasmid Relevant Characteristics Reference
S. aureus
Newman NCTC 8178 wildtype Duthie and Lorenz, 1952
Newman spa Newman spa::Kar defective in protein A O’Brien et al, 2002
Plasmids
pCU1spa+ Shuttle vector capable of replicating in E. coli and S. aureus. Cmr Apr
spa gene cloned into pCU1
Claro et al, 2011
doi:10.1371/journal.pone.0040586.t003
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After 30 minutes incubation at 37uC, the reaction was stopped
using 1 M NaOH. Absorbance was then read at A405nm, using a
microplate reader (Wallac Victor2, United Kingdom).
Statistical Analysis
All statistical analysis was performed using a two-tailed
Student’s t-test with the statistical software SSC-Stat V2.12. Data
were represented as the mean values +/2 the standard error of the
mean (SEM). All values were considered significant at P,0.05.
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